THE RELATIONSHIP OF MAGNOLOL, AN IMPORTANT PHYTOCONSTITUENT, WITH NEUROLOGICAL DISORDERS: An In silico EVALUATION
ABHINAV ANAND
School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab- 144411, India and CT Institute of Pharmaceutical Sciences, CT Group of Institutions, Shahpur, Jalandhar, Punjab-144020, India.
V. NUTHAN KUMAR BABU
School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab- 144411, India.
RAGHUNATH GIRIYAM
School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab- 144411, India.
SACHIN TURAN
CT Institute of Pharmaceutical Sciences, CT Group of Institutions, Shahpur, Jalandhar, Punjab-144020, India.
. REEMA
Shree Lakshmi Narayan Ayurvedic College and Hospital, Amritsar, Punjab-143009, India.
NEHA SHARMA
School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab- 144411, India.
NAVNEET KHURANA *
School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab- 144411, India.
MANISH VYAS
School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab- 144411, India.
*Author to whom correspondence should be addressed.
Abstract
Purpose of the work: While the world is going towards financially straining research on synthetic molecules, there are several phytochemicals that are still not explored to the fullest of their potential. Magnolol is a polyphenolic compound obtained from the root and stem bark of Magnolia species. The roots and bark of the plants have been in use for ages in Japanese and Chinese traditional medicine systems for the treatment of several neurological disorders. Magnolol can be explored for its beneficial effects in neurological disorders in vivo.
Techniques and methods used: This study aims to estimate the physicochemical properties, pharmacokinetics, toxicology of magnolol in silico with the help of online programs like SwissADME and admetSAR. Further, various possible biological activities have been predicted using another in silico model i.e., Prediction of Activity Spectra of Substances (PASS) online.
Major findings: Magnolol has been reported to be a slightly water soluble compound with high gastrointestinal absorption and a capability of permeating the Blood Brain Barrier. It has been predicted to have antioxidant activity along with membrane protecting capability. It has also been predicted to have beneficial effects in neurological disorders including but not limited to dementia. It has been estimated to belong to ‘Category III’ products for oral toxicity. Also, it has been estimated to be non-carcinogenic.
Conclusion: Magnolol has several desirable characteristics that make it an appropriate choice for in vivo evaluation for several neurological disorders like anxiety, depression, Parkinson’s disease, Alzheimer’s disease, to name a few.
Keywords: Magnolol, in silico, pharmacokinetics, toxicology, neurological disorders.